{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:13:13Z","timestamp":1792008793376,"version":"4.4.0"},"reference-count":57,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The absence of a unifying pathogenetic mechanism in metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has significantly hindered therapeutic progress. Appreciation that the delivery of excessive amounts of calories to the liver via the portal circulation might be a key parallel between MASLD and the twin steatotic liver disease, alcohol-related liver disease (ALD), establishes a consolidated framework that could guide rational drug design and precise therapeutic approaches. This review contends that, in both ALD and MASLD, the unique dual blood supply to the liver, from both portal vein and hepatic artery as well as the distinctive blood flow control physiology, prevents hepatic arterial oxygen delivery from adequately compensating for the increased metabolic demands induced by excess caloric intake\u2014alcohol in ALD and food in MASLD\u2014resulting in hepatocellular injury. Over four decades ago, Lautt postulated that this \u2018oxygen-nutrient mismatch\u2019 could play a role in ALD. We have extended this paradigm to MASLD, theorizing that analogous mechanisms may be involved in both conditions. Evidence that comorbidities, which are associated with recurrent episodes of hypoxemia, such as obstructive sleep apnea (OSA), exacerbate MASLD progression, supports this. ALD is less strongly linked to metabolic syndrome than MASLD. This may be due to inherent differences in hepatic substrate processing. Carbohydrates, lipids, and proteins undergo diverse and flexible cytosolic metabolic pathways, especially under metabolic stress. In contrast, hepatic ethanol metabolism is predominantly linear and obligately oxidative, providing limited metabolic adaptability. Future perspectives could focus on rectifying the imbalance between hepatic oxygen delivery and nutrient availability. This might be accomplished by attenuating hepatic caloric excess using emerging pharmacotherapies for weight reduction, augmenting hepatic oxygenation through hyperbaric oxygen therapy, or increasing hepatic arterial blood flow with agents such as obeticholic acid. Furthermore, enhancement of hepatic basal metabolic activity with thyroid hormone receptor-\u03b2 agonists, like resmiritom may confer similar therapeutic effects.<\/jats:p>","DOI":"10.3390\/jcm14248872","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:57:24Z","timestamp":1765879044000},"page":"8872","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): New Perspectives on an Evolving Epidemic"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3954-0429","authenticated-orcid":false,"given":"Gerond","family":"Lake-Bakaar","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"},{"name":"Department of Medicine, Saint Anthony Hospital, Lakewood, CO 80228, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","first-page":"283","article-title":"Nonalcoholic fatty liver disease","volume":"8","author":"Schaffner","year":"1986","journal-title":"Prog. Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"96\u201397, 101\u2013104","DOI":"10.3949\/ccjm.67.2.96","article-title":"The spectrum of nonalcoholic fatty liver disease: From steatosis to nonalcoholic steatohepatitis","volume":"67","author":"Saadeh","year":"2000","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_4","unstructured":"Lake-Bakaar, G. (2017). Alcohol and the Liver, Nova Biomedical."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0044-1785196","article-title":"New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice","volume":"44","author":"Canivet","year":"2024","journal-title":"Semin. Liver. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/gutjnl-2020-323202","article-title":"From the origin of NASH to the future of metabolic fatty liver disease","volume":"70","author":"Geier","year":"2021","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.RES.59.5.483","article-title":"Autoregulation of blood flow","volume":"59","author":"Johnson","year":"1986","journal-title":"Circ. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0676.1993.tb00602.x","article-title":"Hepatic arterial and portal venous oxygen content and extraction in liver cirrhosis","volume":"13","author":"Sezai","year":"1993","journal-title":"Liver"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1113\/expphysiol.1911.sp000086","article-title":"The vascularity of the liver: The influence of the portal blood flow upon the flow in the hepatic artery","volume":"4","year":"1911","journal-title":"Quart. J. Exp. Physiol. Cogn. Med. Sci."},{"key":"ref_10","first-page":"H559","article-title":"Control of hepatic arterial blood flow: Independence from liver metabolic activity","volume":"239","author":"Lautt","year":"1980","journal-title":"Am. J. Physiol."},{"key":"ref_11","unstructured":"Lautt, W.W. (1981). Role and Control of the Hepatic Artery. Hepatic Circulation in Health and Disease, Raven Press."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1139\/y96-029","article-title":"The 1995 Ciba-Geigy Award Lecture. Intrinsic regulation of hepatic blood flow","volume":"74","author":"Lautt","year":"1996","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_13","first-page":"G549","article-title":"Mechanism and role of intrinsic regulation of hepatic arterial blood flow: Hepatic arterial buffer response","volume":"249","author":"Lautt","year":"1985","journal-title":"Am. J. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1002\/ctd2.98","article-title":"The effect of obeticholic acid on hepatic blood flow in isolated, perfused porcine liver: Correction of oxygen-nutrient mismatch might be a putative mechanism of action in NASH","volume":"2","author":"Robertson","year":"2022","journal-title":"Clin. Transl. Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2011.04.022","article-title":"Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese","volume":"56","author":"Minville","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.metabol.2016.05.004","article-title":"Nonalcoholic fatty liver disease and obstructive sleep apnea","volume":"65","author":"Clement","year":"2016","journal-title":"Metabolism"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/thoraxjnl-2015-207212","article-title":"New insights in the pathophysiology of chronic intermittent hypoxia-induced NASH: The role of gut-liver axis impairment","volume":"70","author":"Pepin","year":"2015","journal-title":"Thorax"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1055\/s-0038-1675236","article-title":"Impact of Graft Steatosis on Postoperative Complications after Liver Transplantation","volume":"4","author":"Ahmed","year":"2018","journal-title":"Surg. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/oby.2011.240","article-title":"Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity","volume":"19","author":"Drager","year":"2011","journal-title":"Obesity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2011.09.002","article-title":"Chronic intermittent hypoxia: A breath of fresh air in the understanding of NAFLD pathogenesis","volume":"56","author":"Lemoine","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s11325-018-1622-x","article-title":"Effect of CPAP therapy on liver disease in patients with OSA: A review","volume":"22","author":"Liu","year":"2018","journal-title":"Sleep Breath."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1164\/rccm.201806-1109TR","article-title":"Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease","volume":"199","author":"Mesarwi","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0032-1306426","article-title":"Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: Emerging evidence and mechanisms","volume":"32","author":"Musso","year":"2012","journal-title":"Semin. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.14740\/gr1033w","article-title":"A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy","volume":"11","author":"Bajantri","year":"2018","journal-title":"Gastroenterol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.5664\/jcsm.7262","article-title":"Continuous Positive Airway Pressure Therapy on Nonalcoholic Fatty Liver Disease in Patients With Obstructive Sleep Apnea","volume":"14","author":"Kim","year":"2018","journal-title":"J. Clin. Sleep Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jpeds.2018.03.028","article-title":"Treating Obstructive Sleep Apnea and Chronic Intermittent Hypoxia Improves the Severity of Nonalcoholic Fatty Liver Disease in Children","volume":"198","author":"Sundaram","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1530\/JOE-19-0555","article-title":"Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2alpha","volume":"246","author":"Yu","year":"2020","journal-title":"J. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Emanuele, F., Biondo, M., Tomasello, L., Arnaldi, G., and Guarnotta, V. (2025). Ketogenic Diet in Steatotic Liver Disease: A Metabolic Approach to Hepatic Health. Nutrients, 17.","DOI":"10.3390\/nu17071269"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"156028","DOI":"10.1016\/j.metabol.2024.156028","article-title":"The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus","volume":"161","author":"Zeng","year":"2024","journal-title":"Metabolism"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.15698\/cst2025.06.305","article-title":"Pathogenic aspects of fructose consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): A narrative review","volume":"9","author":"Burger","year":"2025","journal-title":"Cell Stress"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"109189","DOI":"10.1016\/j.jnutbio.2022.109189","article-title":"Different Types of Dietary Fat and Fructose Interactions Result in Distinct Metabolic Phenotypes in Male Mice","volume":"111","author":"Shi","year":"2023","journal-title":"J. Nutr. Biochem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Luukkonen","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Garcia, S., Monserrat-Mesquida, M., Ugarriza, L., Casares, M., Gomez, C., Mateos, D., Angullo-Martinez, E., Tur, J.A., and Bouzas, C. (2025). Ultra-Processed Food Consumption and Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): A Longitudinal and Sustainable Analysis. Nutrients, 17.","DOI":"10.3390\/nu17030472"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Geladari, E.V., Kounatidis, D., Christodoulatos, G.S., Psallida, S., Pavlou, A., Geladari, C.V., Sevastianos, V., Dalamaga, M., and Vallianou, N.G. (2025). Ultra-Processed Foods and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): What Is the Evidence So Far?. Nutrients, 17.","DOI":"10.3390\/nu17132098"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100352","DOI":"10.1016\/j.jnha.2024.100352","article-title":"Association of ultra-processed food intake with severe non-alcoholic fatty liver disease: A prospective study of 143073 UK Biobank participants","volume":"28","author":"Zhang","year":"2024","journal-title":"J. Nutr. Health Aging"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Arita, V.A., Cabezas, M.C., Hernandez Vargas, J.A., Trujillo-Caceres, S.J., Mendez Pernicone, N., Bridge, L.A., Raeisi-Dehkordi, H., Dietvorst, C.A.W., Dekker, R., and Uriza-Pinzon, J.P. (2025). Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of randomized controlled trials. BMC Med., 23.","DOI":"10.1186\/s12916-025-04320-7"},{"key":"ref_37","first-page":"4209","article-title":"Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index","volume":"70","author":"Channapragada","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Fan, J., Nie, K., Liu, X., Liu, J., and Shao, B. (2025). Exercise ameliorates hepatic lipid accumulation via upregulating serum PRL and activating hepatic PRLR-mediated JAK2\/STAT5 signaling pathway in NAFLD mice. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1647231"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e947157","DOI":"10.12659\/MSM.947157","article-title":"Effects of Weight Loss on Insulin Resistance and Liver Health in T2DM and NAFLD Patients","volume":"31","author":"Yang","year":"2025","journal-title":"Med. Sci. Monit."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14656566.2025.2478917","article-title":"Resmetirom: The first approved therapy for treating metabolic dysfunction associated steatohepatitis","volume":"26","author":"Bhushan","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.59556\/japi.73.1058","article-title":"MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians","volume":"73","author":"Kumar","year":"2025","journal-title":"J. Assoc. Physicians India"},{"key":"ref_42","first-page":"111435","article-title":"Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review","volume":"31","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100058","DOI":"10.1016\/j.pharmr.2025.100058","article-title":"Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease","volume":"77","author":"Rodriguez","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"122806","DOI":"10.1016\/j.lfs.2024.122806","article-title":"Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions","volume":"351","author":"Somabattini","year":"2024","journal-title":"Life Sci."},{"key":"ref_45","first-page":"1162","article-title":"Propranolol versus endoscopic variceal ligation for primary prophylaxis of esophageal varices in cirrhosis: A systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Suffert","year":"2025","journal-title":"Hepatol. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2024-11-3","DOI":"10.7573\/dic.2024-11-3","article-title":"Is carvedilol superior to propranolol in patients with cirrhosis with portal hypertension: A systematic and meta-analysis","volume":"14","author":"Rajpurohit","year":"2025","journal-title":"Drugs Context"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Avram, R.I., Minea, H.O., Huiban, L., Damian, I.R., Muset, M.C., Juncu, S., Muzica, C.M., Zenovia, S., Singeap, A.M., and Girleanu, I. (2025). Advancements in Beta-Adrenergic Therapy and Novel Personalised Approach for Portal Hypertension: A Narrative Review. Life, 15.","DOI":"10.3390\/life15081173"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114885","DOI":"10.1016\/j.biopha.2023.114885","article-title":"Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study","volume":"163","author":"Almenara","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/apt.16189","article-title":"Carvedilol is associated with improved survival in patients with cirrhosis: A long-term follow-up study","volume":"53","author":"McDowell","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hones, G.S., Sivakumar, R.G., Hoppe, C., Konig, J., Fuhrer, D., and Moeller, L.C. (2022). Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213714"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6430023","DOI":"10.1155\/ije\/6430023","article-title":"Resmetirom: The First Disease-Specific Treatment for MASH","volume":"2025","author":"Mousa","year":"2025","journal-title":"Int. J. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Jamal, F., Elshaer, A., Odeh, N.B., Alatout, M.H., Shahin, T., Worden, A.R., Albunni, H.N., Lizaola-Mayo, B.C., Jayasekera, C.R., and Chascsa, D.M.H. (2025). Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Life, 15.","DOI":"10.3390\/life15081306"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"17457","DOI":"10.1021\/acs.jmedchem.5c00994","article-title":"Discovery of Highly Potent, Selective, and Liver-Targeted THR-beta Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis","volume":"68","author":"Liang","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/poh2.100","article-title":"Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"4","author":"Liu","year":"2025","journal-title":"Portal Hypertens. Cirrhosis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1007\/s12013-025-01838-8","article-title":"Pathological Changes in Liver Mitochondria of Rats with Experimentally Induced Hyperthyroidism and Their Correction with Uridine","volume":"83","author":"Venediktova","year":"2025","journal-title":"Cell Biochem. Biophys."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e70920","DOI":"10.1002\/hsr2.70920","article-title":"Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"8","author":"Shakeel","year":"2025","journal-title":"Health Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"230","DOI":"10.28920\/dhm53.3.230-236","article-title":"Contemporary practices of blood glucose management in diabetic patients: A survey of hyperbaric medicine units in Australia and New Zealand","volume":"53","author":"Laupland","year":"2023","journal-title":"Diving Hyperb. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8872\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:29:38Z","timestamp":1766035778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":57,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248872"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248872","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}